Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Alnylam Pharmaceuticals's enterprise value was $18.07B on Nov 11, 2026, against $56.74B a year earlier. Over the last 5 years it ranged from $12.98B to $56.87B, with a median of $24.89B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $18.07B | -63.6% |
| 2025 | Dec 31, 2025 | $49.68B | +80.4% |
| 2024 | Dec 31, 2024 | $27.55B | +27.4% |
| 2023 | Dec 29, 2023 | $21.62B | -19.9% |
| 2022 | Dec 30, 2022 | $26.99B | +49.9% |
| 2021 | Dec 31, 2021 | $18.01B | +35.2% |
| 2020 | Dec 31, 2020 | $13.32B | +20.0% |
| 2019 | Dec 31, 2019 | $11.10B | +80.8% |
| 2018 | Dec 31, 2018 | $6.14B | -43.1% |
| 2017 | Dec 29, 2017 | $10.79B | +329.5% |
| 2016 | Dec 30, 2016 | $2.51B | -64.1% |
| 2015 | Dec 31, 2015 | $7.00B | +2.2% |
| 2014 | Dec 31, 2014 | $6.85B | +76.8% |
| 2013 | Dec 31, 2013 | $3.87B | +432.2% |
| 2012 | Dec 31, 2012 | $727.58M | +316.0% |
| 2011 | Dec 30, 2011 | $174.89M | -5.1% |
| 2010 | Dec 31, 2010 | $184.33M | – |
See a number that looks wrong?